Exoxemis
Exoxemis is a biomedical research company focused on the study and commercialization of Zempia®, a topical biological antiseptic system utilizing Myeloperoxidase (MPO). The company develops haloperoxidase products for prevention and treatment of serious infections, addressing microbial drug resistance, and exploring applications in medical, biodefense, industrial, veterinary, and disinfectant fields. They have completed multiple human clinical trials demonstrating the safety and efficacy of Zempia®, which has broad microbicidal activity and potential to prevent sepsis and combat resistant pathogens.
Industries
Nr. of Employees
small (1-50)
Exoxemis
Arkansas City, Arkansas, United States, North America
Patents
Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid A
US-11389514-B2
View DetailsCompositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
US-8945540-B2
View Details
Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid A
US-11389514-B2
View DetailsCompositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
US-8945540-B2
View DetailsProducts
E-101 topical enzyme-based antimicrobial (porcine-derived haloperoxidase system)
A porcine myeloperoxidase–based topical/local antimicrobial system formulated to generate reactive oxygen species (including singlet oxygen) and selectively bind to pathogens for microbicidal activity in wounds and other local applications.
E-101 topical enzyme-based antimicrobial (porcine-derived haloperoxidase system)
A porcine myeloperoxidase–based topical/local antimicrobial system formulated to generate reactive oxygen species (including singlet oxygen) and selectively bind to pathogens for microbicidal activity in wounds and other local applications.
Services
Clinical-trial laboratory and healthcare lab services including sample preparation, environmental testing, microscopy, chemical research, and pathology testing as listed on the services page.
Negotiation and execution of licensing agreements and strategic collaborations to support further testing, regulatory submissions, and commercialization of enzyme-based antimicrobial technology.
Clinical-trial laboratory and healthcare lab services including sample preparation, environmental testing, microscopy, chemical research, and pathology testing as listed on the services page.
Negotiation and execution of licensing agreements and strategic collaborations to support further testing, regulatory submissions, and commercialization of enzyme-based antimicrobial technology.
Expertise Areas
- Clinical trial management
- Enzyme-based antimicrobial therapeutics
- Preclinical microbiology and infection models
- cGMP biologics manufacturing and scale-up
Key Technologies
- Haloperoxidase enzyme antimicrobial platforms
- Singlet oxygen–generating enzymatic systems
- cGMP protein purification
- In vitro microbiology assays (MIC, MBC, time-kill)
News & Updates
Human Clinical Trials of Zempia®
Completed a placebo-controlled, randomized, international Phase III human clinical trial with 250 subjects at 25 U.S. and 5 Israeli sites, demonstrating safety for use in open wounds.
Research on Zempia®'s Efficacy
Extensive laboratory and animal testing shows Zempia®'s broad microbicidal activity, safety, and potential to prevent sepsis.
Zempia®'s Antiviral and Antimicrobial Properties
Studies demonstrating Zempia®'s viricidal properties against coronavirus, herpes simplex, HIV, and influenza, as well as activity against resistant pathogens.
A peer-reviewed article published in the Journal of Immunology Research demonstrating MPO's ability to inactivate endotoxins and improve survival in a mouse model.
Publication of a peer-reviewed article showing MPO's potential in fighting sepsis by inactivating endotoxins.
Human Clinical Trials of Zempia®
Completed a placebo-controlled, randomized, international Phase III human clinical trial with 250 subjects at 25 U.S. and 5 Israeli sites, demonstrating safety for use in open wounds.
Research on Zempia®'s Efficacy
Extensive laboratory and animal testing shows Zempia®'s broad microbicidal activity, safety, and potential to prevent sepsis.
Zempia®'s Antiviral and Antimicrobial Properties
Studies demonstrating Zempia®'s viricidal properties against coronavirus, herpes simplex, HIV, and influenza, as well as activity against resistant pathogens.
A peer-reviewed article published in the Journal of Immunology Research demonstrating MPO's ability to inactivate endotoxins and improve survival in a mouse model.
Publication of a peer-reviewed article showing MPO's potential in fighting sepsis by inactivating endotoxins.